Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vivoryon Therapeutics N.V. has announced promising new data showing that its drug varoglutamstat significantly improves kidney function in diabetic patients. In addition to kidney benefits, the treatment also exhibited potential health improvements including weight loss and lower blood pressure without notable adverse events. The company is now planning to advance the drug into a Phase 2 clinical study for diabetic kidney disease.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.